The Holding Company Behind PatentVest: Why MDB Capital's Portfolio May Be Worth More Than Its Market Cap

The Holding Company Behind PatentVest: Why MDB Capital's Portfolio May Be Worth More Than Its Market Cap

MDB Capital Holdings, LLC (NASDAQ: MDBH) isn't a traditional operating company — it's a publicly traded venture platform with a unique mandate: identify deep technology companies with significant intellectual property, help them go public on NASDAQ, and retain equity exposure to their growth. Founded in 1997 and based in Addison, Texas, the company operates through three subsidiaries: MDB CG Management Company (the holding company's management arm), Public Ventures, LLC (a self-clearing broker-dealer registered with the SEC and FINRA/SIPC), and PatentVest — an AI-enabled intellectual property intelligence, strategy, and law firm that has become the company's most differentiated asset.

PatentVest: The IP Intelligence Engine

The most compelling part of the MDB story may be PatentVest, and it deserves a closer look. Built originally in 2003 as MDB's proprietary patent analytics platform, PatentVest has evolved into what the company describes as the first integrated IP intelligence, strategy, and law firm — one designed specifically for companies where patents drive enterprise value.

PatentVest combines proprietary patent intelligence data, AI-driven analytics, and expert legal analysis to deliver actionable insights for innovation-driven organizations. Its recent work speaks to the sophistication of the platform:

OpenAI patent portfolio analysis: PatentVest's Pulse report analyzed all 69 published patent families owned by OpenAI, covering approximately 35 underlying inventions across 13 technology categories. The report examined what those patents reveal about OpenAI's strategy and what they may signal about the future of competition in generative AI — the kind of deep, structured IP analysis that traditional law firms don't produce.

Brain-computer interface (BCI) market mapping: PatentVest published a first-of-its-kind report mapping the competitive and IP landscape of the $400 billion BCI market, combining company-level benchmarking with comprehensive patent portfolio analysis.

AI data center patent race: A Pulse report examining transformative trends in how companies are patenting AI infrastructure technology — an area where IP positioning will likely determine competitive advantage for years to come.

For MDB, PatentVest serves a dual purpose: it's a revenue-generating service business (providing IP strategy to external clients) and a proprietary research edge (helping MDB identify which deep technology companies have the strongest patent moats before investing in or underwriting them). That combination — external revenue plus internal investment edge — is genuinely uncommon in the financial services landscape.

MDB has signaled its intent to spin PatentVest off as an independent company, a move that could allow the IP platform to scale without the constraints of the holding company structure and potentially unlock value that the current consolidated structure obscures.

The Public Venture Model

Beyond PatentVest, MDB's broader model is worth understanding. Through Public Ventures, LLC, the company operates a self-clearing broker-dealer platform that took nearly five years to build — a significant infrastructure investment that allows MDB to underwrite and distribute early-stage technology IPOs without relying on third-party clearing firms. The platform also includes MDB Direct, a self-directed brokerage offering that lets retail investors participate in early-stage offerings typically reserved for institutional accounts.

The model works as a closed loop: PatentVest identifies companies with strong IP positioning, MDB's investment banking arm underwrites their public offerings, the company takes equity stakes in the companies it helps list, and the brokerage platform gives investors access to those offerings. Revenue comes from investment banking fees, brokerage commissions, and eventually the appreciation of equity positions in portfolio companies.

The Portfolio: Where the Value Resides

MDB's equity portfolio is the bridge between its market cap and its underlying value. As of the company's 2025 full-year update:

eXoZymes (NASDAQ: EXOZ): MDB holds approximately 4.1 million shares and warrants. At the July 31, 2026 closing price of $4.65, that position is valued at approximately $19 million — roughly 60% of MDB's $32 million market cap in a single holding. When MDB last disclosed this position in its March 2026 update, EXOZ was trading higher and the stake was valued at approximately $30 million; the position's mark-to-market value has declined alongside EXOZ's share price since then.

Paulex Bio: MDB holds approximately 7.1 million shares and warrants. Paulex closed a $19 million seed round during 2025, fully funding its development program. The company is developing an oral medication designed to address the root cause of a significant disease, and is targeting an IPO for September 2026.

Sarcomatrix Therapeutics: An earlier-stage position, with Sarcomatrix having engaged PatentVest for intellectual property strategy — a tangible example of how the IP platform feeds into the investment pipeline.

On the balance sheet side, MDB reported $22.3 million in net assets — cash, current assets, and marketable securities less all liabilities — at year-end 2025. Combined with the EXOZ position (approximately $19 million at current prices), that's roughly $41 million in identifiable value against a $32 million market cap. The Paulex Bio position, the PatentVest platform, the Public Ventures broker-dealer, and the investment banking operations all sit on top of that — and are effectively being assigned minimal or no value by the market at current prices.

Financials: Revenue Growth in an Investment Phase

MDB's revenue is growing meaningfully. Q1 2026 revenue came in at approximately $3.09 million, up roughly 89% year-over-year and 23% sequentially. Trailing twelve-month revenue sits in the $4.6–$5.2 million range, driven by investment banking fees and brokerage activity through Public Ventures.

The company is in a significant investment phase, with net operating expenses exceeding revenue as it scales the Public Ventures infrastructure, expands PatentVest's capabilities, and funds its portfolio companies. Net loss for the trailing twelve months was approximately $21 million — a figure that reflects the cost of building a self-clearing broker-dealer (a five-year infrastructure project), growing an AI-enabled IP intelligence platform, and maintaining equity exposure to early-stage companies. The $22.3 million net asset base provides a runway, and the planned spin-offs could improve capital efficiency by letting each business operate with its own financial profile.

Leadership and Governance

Co-founder Christopher Marlett continues to lead MDB as CEO, bringing nearly three decades of experience in deep technology investing and public venture banking. The board has been actively restructured: Jeb Terry, Sr. was appointed to the board effective February 1, 2026, bringing additional governance depth. Managing Director Edgardo Rayo, CFA, leads the investment analysis team, which applies MDB's proprietary investment criteria — including PatentVest's IP analytics — to evaluate deep technology opportunities before committing capital or underwriting an offering.

The Bull Case

The arithmetic is straightforward: identifiable portfolio value ($19M in EXOZ plus $22.3M in net assets) exceeds the entire market cap ($32M), meaning the operating businesses — investment banking, the self-clearing brokerage, and PatentVest's IP intelligence platform — are being assigned minimal value by the market. Revenue is growing rapidly (89% YoY in Q1 2026). The Paulex Bio IPO in September 2026 could be a meaningful catalyst, potentially monetizing a 7.1 million-share position. The PatentVest spin-off could crystallize the value of an AI-enabled IP platform that has already produced institutional-grade research on OpenAI, brain-computer interfaces, and AI data center patents. And the "public venture" model itself, if it scales, addresses a genuine gap in the market — traditional investment banks don't take early-stage deep tech companies public, and venture funds don't offer their investors the liquidity of a public listing.

The Bear Case

Operating expenses are running ahead of revenue, and the net asset base, while meaningful, is being drawn down to fund the company's growth trajectory. The portfolio's value is mark-to-market — EXOZ has already declined from approximately $7.30 per share (implied by MDB's March valuation) to $4.65 at July 31, reducing the position value from roughly $30 million to $19 million. The stock is thinly traded (daily volume under 1,500 shares), which creates practical challenges for investors looking to establish or exit positions. The public venture model is still early-stage as a business category, and the companies MDB underwrites are themselves early-stage and subject to the typical challenges of pre-revenue or pre-profit technology ventures. The planned spin-offs, while strategically logical, add execution layers that require management attention and capital.

Scoring and Quadrant Classification

Asset Quality / Execution (Signal Score): 6/10 — Real portfolio holdings with tangible market values, a built and operational self-clearing broker-dealer, an AI-enabled IP intelligence platform with published institutional-grade research, and accelerating revenue growth. The investment-phase expense structure is a factor that keeps the score moderate rather than elevated.

Promotion Intensity (Hype Score): 4/10 — MDB maintains a professional investor relations program with annual shareholder letters, press releases, and an investor-facing website, but the company isn't engaged in aggressive retail promotion. News flow tracks operational events — portfolio updates, PatentVest Pulse reports, board transitions — rather than speculative marketing.

Quadrant Label: Hidden Value / Deep Value — Identifiable portfolio and net asset value that exceeds the market cap, paired with modest promotion and genuine operating businesses, places MDB in the hidden value category. The gap between asset value and market price is the thesis; the question is whether the spin-offs and portfolio monetization will narrow that gap over the next 12–18 months.

📊 Scoring GuideAsset Quality / Execution (1–10)Measures tangible, verifiable fundamentals — revenue growth, profitability, contracts, institutional backing, and proprietary technology. A higher score indicates a company with real, derisked business performance.Promotion Intensity (1–10)Measures the volume of investor relations marketing, press release cadence, retail buzz, and promotional activity relative to actual operational progress. A higher score indicates more hype relative to substance.Market Leader / Catalyst PlayHigh asset quality + High promotion. Real business with active market attention.Hidden Value / Deep ValueHigh asset quality + Low promotion. Overlooked company with solid fundamentals.Pure Promote / Pump RiskLow asset quality + High promotion. Heavy promotion with limited operational substance.Zombie Stock / DormantLow asset quality + Low promotion. Limited activity and minimal market interest.

The Bottom Line

MDB Capital Holdings presents a structural question that the market hasn't fully answered yet: what is a publicly traded venture platform with an AI-enabled IP intelligence subsidiary, a self-clearing broker-dealer, and a portfolio worth more than its own market cap actually worth? The company's investment phase means capital is being deployed to build infrastructure and fund portfolio companies rather than generate near-term profitability — a dynamic that requires patience from shareholders. With PatentVest's spin-off on the horizon and a Paulex Bio IPO targeted for September, the next 12 months could provide the first real test of whether the sum of the parts exceeds the whole.

Todd Colpron is the Managing Partner of Eliakim Capital, a private investment and strategic advisory firm that invests its own capital and co-invests with a family office.